Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4609 News 


«12...4567891011121314...5758»
  • ||||||||||  Review, Journal:  Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj (Pubmed Central) -  May 8, 2023   
    Second-line therapy with baricitinib, bortezomib, eculizumab, secukinumab, or tocilizumab can be considered in SLE-specific manifestations. These evidence and practice-based recommendations may support treatment decision and, ultimately, improve the outcome of patients living with SLE, APS, or SS.
  • ||||||||||  Empaveli (pegcetacoplan SC) / Apellis, SOBI
    Journal:  Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. (Pubmed Central) -  May 8, 2023   
    We validated the selected algorithm using EQ-5D-5L utilities converted from EORTC QLQ-C30 data collected in the PEGASUS phase III, randomized controlled trial of pegcetacoplan versus eculizumab in adults with PNH. Selected through the genetic algorithm, the ordinary least squares model without interactions provided highly stable results across study visits (mean [
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
    Trial completion:  ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Na (clinicaltrials.gov) -  May 6, 2023   
    P3,  N=270, Completed, 
    Selected through the genetic algorithm, the ordinary least squares model without interactions provided highly stable results across study visits (mean [ Active, not recruiting --> Completed
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  A case of malignant hypertension as a (Pubmed Central) -  May 5, 2023   
    mHTN is a common presentation of aHUS. In cases of mHTN, abnormalities in complement-related genes may be involved in the development of the disease.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    THE MULTIVERSE OF PREGNANCY-ASSOCIATED AHUS: TRIGGERS, TIMING AND OUTCOMES  (Focussed Oral Room 4) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1980;    
    Moreover, one patient suspended infusion with close monitoring. Hence, we hope that these clinical records could help to improve the awareness of this manifold syndrome and to emphasize the importance of an early diagnosis and a timely treatment with eculizumab to guarantee full pregnants' recovery.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    RATIONAL USE OF ECULIZUMAB IN SECONDARY ATYPICAL HAEMOLYTIC UREMIC SYNDROME (Focussed Oral Room 2) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1863;    
    Large studies are needed in order to better define clinical and histological predictors of adverse renal outcome as well as the optimal treatment regimens. Rational and early use of Eculizumab in patients with secondary aHUS could be an effective and safe therapeutic option, guaranteeing better renal recovery compared to patients who do not receive complement blockade.NA Commented [CdS1]: a significant difference in renal response
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    ONCO-NEPHROLOGY: THE ROLE OF KIDNEY BIOPSY IN THE MANAGEMENT OF SIDE EFFECTS OF TARGETED THERAPIES (Focussed Oral Room 2) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1796;    
    A patient with severe thrombotic microangiopathy requiring dialysis received a treatment with eculizumab for 3 months... Kidney biopsy is critical for the management of kidney toxicities and should be strongly encouraged for patients showing adverse kidney effects of novel cancer agents.
  • ||||||||||  Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
    RAVULIZUMAB "DE NOVO" IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLITIC UREMIC SYNDROME: FIRST WORLDWIDE CASES (Focussed Oral Room 5) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_909;    
    Deterioration of general condition, with laboratory tests compatible with thrombotic microangiopathy (TMA), evolves to anuria and convulsive episode requiring invasive mechanical ventilation, corticosteroid boluses, 6 plasmapheresis sessions and 4 intermittent hemodialysis. One Eculizumab dose (600mg) was administered in the center of origin and STEC was isolated.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    AN ATYPICAL EXPERIENCE FOR THE WEST OF SCOTLAND (Focussed Oral Room 5) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_835;    
    Furthermore, in those for whom transplantation is being considering, it is imperative that Eculizumab is introduced, if already withdrawn, to cover transplantation and is maintained to prevent recurrence in the new organ. Even in those without RRT requirements, use of the C5 inhibitor is necessary to stabilise and allow for recovery of at least some native function.
  • ||||||||||  Review, Journal:  Monoclonal antibodies for treatment of cold agglutinin disease. (Pubmed Central) -  May 2, 2023   
    Future antibody-based treatment approaches for CAD involve the further development of complement-directed antibodies, combination of rituximab and bortezomib, and daratumumab. Non-antibody based prospective treatments may include the use of Bruton tyrosine kinase inhibitors.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Evaluation of Eculizumab Use in Renal Transplant Recipients. (Pubmed Central) -  May 1, 2023   
    Eculizumab treatment demonstrated a benefit on graft and patient survival compared to reported incidence in thrombotic microangiopathy and antibody-mediated rejection. Due to the small sample size and retrospective design, further research is warranted to confirm these results.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal, HEOR:  A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder. (Pubmed Central) -  Apr 28, 2023   
    Post hoc analyses of data pooled from the PREVENT study and its open-label extension, which evaluated the efficacy and safety of eculizumab in AQP4+ NMOSD, examined the effect of a single relapse on 3 disability and 4 HRQoL outcome measures...Extrapolating the effect of 2 relapses predicted that clinically meaningful worsening was more likely in 6 out of 7 outcomes, including EDSS, for patients experiencing multiple relapses versus patients experiencing no relapses. Findings from these clinical trial data demonstrate that a single NMOSD relapse can worsen disability and HRQoL, underscoring the role of relapse prevention in improving long-term outcomes in patients with AQP4+ NMOSD.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, crovalimab (RG6107) / Roche, pozelimab (REGN3918) / Regeneron
    Journal:  Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5. (Pubmed Central) -  Apr 24, 2023   
    A similar pattern of complexes was also observed when fluorescently labeled eculizumab and either of the other two antibodies were spiked into human plasma, based on SEC monitored by fluorescence detection. A detailed characterization of the pharmacodynamic and pharmacokinetic properties of such complexes is warranted, as is the incorporation of mitigation processes to avoid their formation in patients converting from one bivalent, noncompetitive, C5-binding monoclonal antibody to another.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Emerging Therapeutic Options for Chronic Active ABMR (Room 4) -  Apr 15, 2023 - Abstract #KSN2023KSN_96;    
    Multivariable Cox proportional hazard regression analysis showed that age of the donor and t-score of Banff classification before the treatments were significantly associated with worsening of chronic ABMR with severe IFTA. In this session, I would give a talk about recent strategies for chronic ABMR at Tokyo Women's Medical UNiversity Hospital.
  • ||||||||||  gemcitabine / Generic mfg.
    A Case of Gemcitabine Induced Hemolytic Uremic Dyndrome () -  Apr 6, 2023 - Abstract #AFMRSER2023AFMR_SER_37;    
    Myelosuppression is the most common side effect, while CM-TMA is reported in less than 0.01-4% of cases.Eculizumab, a monoclonal antibody, is a novel first-line therapy that targets C5 to inhibit the terminal complement cascade. It has shown favorable outcomes and possible complete renal recovery.Although such presentation is rare with gemcitabine, worsening hypertension, renal function, anemia, and peripheral edema should prompt a high clinical suspicion of gemcitabine-induced TMA.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Newly Engineered IgM and IgG Cleaving Enzymes for AAV Gene Therapy (Room 411) -  Apr 6, 2023 - Abstract #ASGCT2023ASGCT_842;    
    Results demonstrating clearance of neutralizing human IgM + IgG upon dosing recombinant IceM and IceMG accompanied by rescue of AAV transduction in passively immunized mice will be presented. Taken together, our newly engineered enzyme platform has implications for expanding the patient cohort and vector redosing in AAV gene therapies.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca, Empaveli (pegcetacoplan SC) / Apellis, SOBI
    Journal, HEOR:  Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Na (Pubmed Central) -  Apr 5, 2023   
    P3
    Taken together, our newly engineered enzyme platform has implications for expanding the patient cohort and vector redosing in AAV gene therapies. Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-na